Analytica chimica acta

Detecting mycobacterial DNA in lung disease using CRISPR at the species level

Updated

Abstract

CADEM accurately identified all 7 positive cases of MAC, MABC, and MTB in a validation set of 20 clinical specimens without any false positives.

  • CADEM utilizes a microfluidic platform for high-yield recovery of bacterial-derived circulating cell-free DNA from large-volume clinical samples.
  • The system achieves 10- to 100-fold greater sensitivity than traditional PCR methods in detecting specific mycobacterial species.
  • Fluorescence detection from the CRISPR step occurs within 20 minutes, enabling rapid results.
  • The entire diagnostic workflow, from cfDNA enrichment to species-level results, is completed within 2 hours.
  • CADEM may facilitate accurate diagnosis and treatment of pulmonary infections caused by mycobacteria.
  • The technology is adaptable for point-of-care testing in resource-limited settings.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of competing interest The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free